MT-ATP6 and type 2 diabetes mellitus: These outcomes highlighted the potential of targeting the miR-378a/mt-ATP6 axis via Kcnq1ot1 overexpression to address comorbidity complications in T2DM, improve patient outcomes, and slow disease progression (Durr et al., 2022).